Angela Koutsokera1, Daiana Stolz2, Stelios Loukides3, Konstantinos Kostikas4. 1. Service de Pneumologie et Rehabilitation Respiratoire, Hôpital de Rolle, Switzerland. 2. Clinic for Pulmonary Medicine and Respiratory Cell Research, University Hospital, Basel, Switzerland. 3. Second Respiratory Medicine Department, University of Athens Medical School, Athens, Greece. 4. Second Respiratory Medicine Department, University of Athens Medical School, Athens, Greece. Electronic address: ktk@otenet.gr.
Abstract
BACKGROUND: Exacerbations of COPD (ECOPD) remain a major cause of mortality and morbidity. Despite advances in the understanding of their pathophysiology, their assessment relies primarily on clinical presentation, which can be variable and difficult to predict. A large number of biomarkers already have been assessed in this context, and some appear to be promising. METHODS: An online search for articles published until December 2010 was conducted using three terms for ECOPD, five terms for biomarkers, and five terms for the sampling method. Biomarkers were evaluated for their potential role in the establishment and confirmation of the diagnosis of ECOPD, the evaluation of etiology and severity, the prediction of prognosis, and the guidance of treatment decisions. RESULTS: Several systemic biomarkers have been measured in the context of ECOPD, and most have been found to increase at ECOPD onset and to subside during the course of exacerbations. Correlations have been reported among these biomarkers, but direct associations with clinical variables have been more difficult to establish. Although there are several limitations yet to be addressed, some of the biomarkers, most notably C-reactive protein for the identification of an ECOPD and procalcitonin for antibiotic guidance, may provide clinically relevant information. CONCLUSIONS: So far, no single biomarker has been able to gain wide acceptance, but some provide clinically useful information. The evaluation of such biomarkers in large decision-making studies is expected to become an area of intense investigation in the near future.
BACKGROUND: Exacerbations of COPD (ECOPD) remain a major cause of mortality and morbidity. Despite advances in the understanding of their pathophysiology, their assessment relies primarily on clinical presentation, which can be variable and difficult to predict. A large number of biomarkers already have been assessed in this context, and some appear to be promising. METHODS: An online search for articles published until December 2010 was conducted using three terms for ECOPD, five terms for biomarkers, and five terms for the sampling method. Biomarkers were evaluated for their potential role in the establishment and confirmation of the diagnosis of ECOPD, the evaluation of etiology and severity, the prediction of prognosis, and the guidance of treatment decisions. RESULTS: Several systemic biomarkers have been measured in the context of ECOPD, and most have been found to increase at ECOPD onset and to subside during the course of exacerbations. Correlations have been reported among these biomarkers, but direct associations with clinical variables have been more difficult to establish. Although there are several limitations yet to be addressed, some of the biomarkers, most notably C-reactive protein for the identification of an ECOPD and procalcitonin for antibiotic guidance, may provide clinically relevant information. CONCLUSIONS: So far, no single biomarker has been able to gain wide acceptance, but some provide clinically useful information. The evaluation of such biomarkers in large decision-making studies is expected to become an area of intense investigation in the near future.
Authors: Timothy M Bahr; Grant J Hughes; Michael Armstrong; Rick Reisdorph; Christopher D Coldren; Michael G Edwards; Christina Schnell; Ross Kedl; Daniel J LaFlamme; Nichole Reisdorph; Katerina J Kechris; Russell P Bowler Journal: Am J Respir Cell Mol Biol Date: 2013-08 Impact factor: 6.914
Authors: Alessia Verduri; Fabrizio Luppi; Roberto D'Amico; Sara Balduzzi; Roberto Vicini; Anna Liverani; Valentina Ruggieri; Mario Plebani; Maria Pia Foschino Barbaro; Antonio Spanevello; Giorgio Walter Canonica; Alberto Papi; Leonardo Michele Fabbri; Bianca Beghè Journal: PLoS One Date: 2015-03-11 Impact factor: 3.240
Authors: Olaf Holz; Benjamin Waschki; Stefan Roepcke; Henrik Watz; Gereon Lauer; Cornelia Faulenbach; Jens M Hohlfeld Journal: BMC Pulm Med Date: 2014-03-01 Impact factor: 3.317